Museum Prescription by a Physician for a Visit to the MBAM (PM)

Museum Prescription by a Physician for a Visit to the Montreal Museum of Fine Arts: Assessment of Effects.

In recent years, museums have participated in the patient care journey by using art to enhance their quality of life and well-being. Since 2015, the Montreal Museum of Fine Arts (MMFA) and Dr. Beauchet have developed an Action-Research program exploring the effects of participatory art activities for community elders conducted at the MMFA, known as the Arts & Longevity Lab (ALL). The mandate of ALL is to improve the well-being, quality of life and health (i.e. mental and physical state) of individuals and patients through the practice of visual arts activities (i.e. arts that produce objects perceived by the eyes).

Since 2019, the MMFA has developed in collaboration with Médecins Francophones du Canada museum visits prescribed by a primary care physician as a new intervention. Today, it is necessary to improve the knowledge on the effects of this museum visit prescription

The overall objective of this study is to examine the effects of a visit to the MMFA prescribed by a primary care physician on the mental health (well-being and quality of life) of patients living in Montreal.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montréal, Quebec, Canada, H3W 1W5
        • CRIUGM

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • age 18 and over
  • having Internet access at home with an electronic device (computer, keyboard, or smartphone)
  • having no dementia
  • speaking English or French
  • committing to visiting the museum within 3 months of the prescription.

Exclusion Criteria:

  • individuals participating in a clinical trial at the same time, to avoid interference with the results of the intervention being studied in this protocol
  • individuals with dementia. There are no tests for dementia. The physicians involved in the pre-recruitment process are aware of the cognitive status of their patients. Therefore, they will be able to avoid offering the study to a patient with dementia if such a diagnosis appears in the medical file.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention

Physicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research.

If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study.

After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit.

The intervention is a visit of the MMFA. This visit can be done alone or accompanied.

The visit of the MMFA is free for the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life
Time Frame: 3 months

Quality of life will be assessed using the EuroQol-5D (EQ-5D).

EuroQol-5D is composed of two parts:

  • a five-question questionnaire with a score per question ranging from 1 (no problem) to 5 (severe problem), so that the sum ranged from 0 (no problem) to 25 (severe problem).
  • a visual analogue scale on participants' perceived health. This scale is numbered from 0 (i.e., the worst health the participant can imagine) to 100 (i.e., the best health the participant can imagine).

This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

3 months
Well-being
Time Frame: 3 months

Well-being will be assessed using the Warwick-Edinburgh Mental Well-being Scale (WEMWBS).

The WEMWBS is a validated questionnaire composed by a 14-item positively worded scale and five response categories. It covers most aspects of positive mental health (positive thoughts and feelings).

This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Health Status
Time Frame: 3 months

Physical health status will be assessed using the CRIUGM Self-AdMinistered questionnaire (CESAM).

The CESAM has been previously developed and validated.

It is composed of 20 items exploring several domains:

  • weight loss and its extent;
  • polypharmacy defined by a number of therapeutic classes taken on a daily basis ≥ 5;
  • vision, hearing, and memory problems;
  • use of home support;
  • 6-item activities of daily living scale, 4-item instrumental activities of daily living scale;
  • mood assessed
  • regular physical activity defined as at least 1 hour per week in the past month;
  • and history of falls in the past 12 months.

The CESAM provides two complementary scores:

  1. An overall frailty score ranging from 0 to 18
  2. A four-stage categorization of frailty

This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

3 months
Social Isolation
Time Frame: 3 months

Social isolation will be assessed using the 11-item Duke Social Support Index (DSSI).

This index includes two subscales:

  • social interaction (i.e., frequency of interactions)
  • subjective support (i.e., satisfaction with emotional support provided).

The DSSI score ranges from 11 to 33, with higher scores indicating higher levels of social inclusion. Scores for the 11 items are combined and categorized as low (score ≤26), high (score 27-29), and very high (score 30-33). We will use the mean score of the 11-item DSSI and its breakdown into three categories as the primary outcome.

This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

3 months
Prescribing context
Time Frame: 3 months
Researchers will also study the prescribing context. A document will be filled by primary care physicians to give additional informations on the prescribing context such as the date of the prescription and the reason of the prescription.
3 months
Satisfaction from the visit to the museum
Time Frame: 3 months
A short questionnaire will be given to participants to the intervention at the end of the visit to the museum. This questionnaire will give additionnal information on the satisfaction from the visit and whether the visit was made alone or accompanied.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 27, 2022

Primary Completion (Actual)

July 21, 2023

Study Completion (Actual)

December 22, 2023

Study Registration Dates

First Submitted

June 30, 2022

First Submitted That Met QC Criteria

June 30, 2022

First Posted (Actual)

July 6, 2022

Study Record Updates

Last Update Posted (Estimated)

February 23, 2024

Last Update Submitted That Met QC Criteria

February 22, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • MP-53-2023-2627

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Museum visit

3
Subscribe